Mydecine Innovations Group Inc. (NEO:MYCO / OTC:MYCOF / FSE:0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that John Ross, the Company’s current Chief Financial Officer has been appointed as Corporate Secretary, effective immediately.
The Company also announces that Mr. Todd Heinzl has resigned from the board of directors of the Company, effective immediately, to pursue other endeavors.
Mr. Ross is a senior financial management professional with more than 30 years of private and public company experience. He was first appointed as the Chief Financial Officer of the Company on September 16, 2022.
About Mydecine Innovations Group Inc.
Mydecine Innovations Group™ is a biotechnology company developing the next generation of innovative medications and therapies to address mental health disorders such as nicotine addiction and post-traumatic stress disorder (PTSD). The core strategy blends advanced technology with an elaborate infrastructure for drug discovery and development. Mydecine’s dedicated multinational team constantly develops new paths for breakthrough treatment solutions in areas with considerable unmet needs. By collaborating with some of the world’s leading specialists, the Company aspires to responsibly speed up the development of breakthrough medications to provide patients with safer and more effective treatment solutions. At the same time, Mydecine’s approach focuses on the next generation of psychedelic medicine by creating innovative compounds with unmatched therapeutic potential through its clinical trial efforts with world-class scientific and regulatory expertise. Founded in 2020, Mydecine is based out of Colorado, USA, with extended offices in Alberta, Canada, and Leiden, Netherlands.